

Title (en)

COMBINED THERAPEUTICAL TREATMENT OF HYPERPROLIFERATIVE DISEASES

Title (de)

KOMBINIERTES THERAPEUTISCHES VERFAHREN ZUR BEHANDLUNG VON HYPERPROLIFERATIVEN KRANKHEITEN

Title (fr)

TRAITEMENT THERAPEUTIQUE COMBINE DES PATHOLOGIES HYPERPROLIFERATIVES

Publication

EP 0800399 B1 20020814 (FR)

Application

EP 96901387 A 19960112

Priority

- FR 9600056 W 19960112
- FR 9500436 A 19950117

Abstract (en)

[origin: WO9622101A1] A medicinal combination of one or more nucleic acids that at least partially inhibit oncogenic cell signalling pathways, and a therapeutic anticancer agent, for use simultaneous, separate or over a period of time to treat hyperproliferative diseases.

IPC 1-7

A61K 31/70; **A61K 33/24**; **A61K 31/7105**; **A61K 31/711**; **A61P 35/00**

IPC 8 full level

A61K 31/335 (2006.01); **A61K 31/435** (2006.01); **A61K 31/70** (2006.01); **A61K 31/7105** (2006.01); **A61K 31/711** (2006.01); **A61K 38/00** (2006.01); **A61K 33/243** (2019.01); **A61K 35/76** (2006.01); **A61K 38/19** (2006.01); **A61K 45/00** (2006.01); **A61K 48/00** (2006.01); **A61P 35/00** (2006.01)

CPC (source: EP KR US)

A61K 31/70 (2013.01 - EP KR US); **A61K 33/243** (2019.01 - EP KR US); **A61K 38/191** (2013.01 - EP KR US); **A61P 9/10** (2018.01 - EP); **A61P 35/00** (2018.01 - EP); **A61P 35/02** (2018.01 - EP); **A61P 43/00** (2018.01 - EP)

C-Set (source: EP US)

1. **A61K 38/191** + **A61K 31/70**
2. **A61K 33/24** + **A61K 31/70**
3. **A61K 31/70** + **A61K 31/70**
4. **A61K 31/70** + **A61K 31/70**
5. **A61K 31/70** + **A61K 31/475**
6. **A61K 31/70** + **A61K 31/47**
7. **A61K 31/70** + **A61K 31/335**
8. **A61K 31/70** + **A61K 2300/00**
9. **A61K 33/24** + **A61K 2300/00**
10. **A61K 38/191** + **A61K 2300/00**

Designated contracting state (EPC)

AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

DOCDB simple family (publication)

WO 9622101 A1 19960725; AT E222109 T1 20020815; AU 4542996 A 19960807; AU 716364 B2 20000224; BR 9606969 A 19971104; CA 2209771 A1 19960725; CA 2209771 C 20120103; CZ 226297 A3 19971015; CZ 298710 B6 20080102; DE 69622989 D1 20020919; DE 69622989 T2 20021205; DK 0800399 T3 20021202; EP 0800399 A1 19971015; EP 0800399 B1 20020814; ES 2180729 T3 20030216; FI 119911 B 20090515; FI 973023 A0 19970716; FI 973023 A 19970716; FR 2729295 A1 19960719; FR 2729295 B1 19970228; HU 229484 B1 20140128; HU P9802423 A2 19990201; HU P9802423 A3 20001128; JP 2008133291 A 20080612; JP 2012036201 A 20120223; JP 4580469 B2 20101110; JP 5031921 B2 20120926; JP H10512559 A 19981202; KR 100385266 B1 20050907; KR 19980701449 A 19980515; MX 9704490 A 19971031; NO 325418 B1 20080421; NO 973197 D0 19970709; NO 973197 L 19970709; PT 800399 E 20021231; SI 0800399 T1 20021231; SK 283989 B6 20040707; SK 95797 A3 19971210; US 2001021395 A1 20010913; US 2004127437 A1 20040701; US 2005209177 A9 20050922; US 6262032 B1 20010717; US 7884082 B2 20110208

DOCDB simple family (application)

FR 9600056 W 19960112; AT 96901387 T 19960112; AU 4542996 A 19960112; BR 9606969 A 19960112; CA 2209771 A 19960112; CZ 226297 A 19960112; DE 69622989 T 19960112; DK 96901387 T 19960112; EP 96901387 A 19960112; ES 96901387 T 19960112; FI 973023 A 19970716; FR 9500436 A 19950117; HU P9802423 A 19960112; JP 2008001848 A 20080109; JP 2011206858 A 20110922; JP 52207896 A 19960112; KR 19970704839 A 19970716; MX 9704490 A 19960112; NO 973197 A 19970709; PT 96901387 T 19960112; SI 9630511 T 19960112; SK 95797 A 19960112; US 41268403 A 20030414; US 81614401 A 20010326; US 87522297 A 19970717